European Radiology:多参数骨MRI在骨转移瘤活检靶点选择中的应用

2022-05-10 shaosai MedSci原创

DWI是一种功能性成像技术,通过将扩散敏感梯度(由b值描述)应用于脂肪饱和的T2加权,恶性肿瘤在扩散加权图像上产生高信号(高b值),而周围正常组织的信号被抑制。

现阶段CT引导下的转移性骨活检的作用和频率越来越高,确定癌症患者的预后、预测反应和检测治疗抗性提供了支持。然而,骨转移一直是众所周知的活检挑战,特别是硬化性骨转移更为显著

DWI是一种功能性成像技术,通过将扩散敏感梯度(由b值描述)应用于脂肪饱和的T2加权,恶性肿瘤在扩散加权图像上产生高信号(高b值),而周围正常组织的信号被抑制。ADC被认为是与肿瘤和骨髓细胞性成反比的定量成像标志物,可用于避免对DWI信号的误解。然而,独特的骨小梁基质和可变的脂肪/水比例可导致健康骨髓的高DWI信号和低ADC。Dixon MRI衍生的相对脂肪分数(rFF)图像通过可视化和量化体素脂肪含量可以起到对DWI信号的补充作用。因此,DWI和rFF的结合应用可以实现对有活的骨转移灶的识别

近日,发表在European Radiology杂志的一项研究评估利用DWI信号、ADC和rFF组合的多参数骨MRI(mpBMRI)识别活动性骨转移的可能性,为临床提供了高诊断活检率和NGS可行性。

本研究回顾了中心介入放射科医生(2013年3月至2021年2月)进行的总共150次CT引导下的骨活检结果43名患者有同期的DWI和rFF图像。在ADC和rFF图像上划出每个活检病变感兴趣区域(ROI),并记录了以下MRI参数:DWI信号强度(SI)的视觉分类,ADC和rFF的平均值、中位数、第10和90分位数。非参数检验用于比较肿瘤阳性/阴性活检和可行/不可行的NGS之间的数值,P值<0.05被视为有意义。 

mpBMRI组合高DWI信号、平均ADC<1100µm2/s和平均rFF<20%可识别肿瘤阳性活检,其灵敏度为82%,特异性为80%,阳性预测值(PPV)为93%(p=0.001),NGS可行性为91%的灵敏度,78%的特异性和91%的PPV(p<0.001)。单一的MRI参数DWI信号、ADC和rFF未能区分肿瘤阳性和肿瘤阴性的活检(每个p>0.082)。在NGS可行的活检中,平均和90分位数的rFF明显较小(每个p < 0.041)。单个ADC参数没有显示出关于NGS可行性的明显差异(每个p>0.292)。

 
 60岁男性前列腺癌右髋臼转移的多参数MRI图像。相对脂肪分数(rFF)、扩散加权(DWI)b50和b900图像和表观扩散系数(ADC)、活检CT(Bx-CT)。在CT图像上无法识别病变

本研究表明,利用DWI信号、ADC和rFF的组合的mpBMRI可以识别适合活检的活动性骨转移,同时提供了高诊断率和NGS可行性,可作为介入影像学工作的一部分,应用于有骨转移的癌症患者的活检病灶选择。

原文出处:

Ricardo Donners,Ines Figueiredo,Nina Tunariu,et al.Multiparametric bone MRI can improve CT-guided bone biopsy target selection in cancer patients and increase diagnostic yield and feasibility of next-generation tumour sequencing.DOI:10.1007/s00330-022-08536-6

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1774632, encodeId=9ee91e7463248, content=<a href='/topic/show?id=6b9b10188e56' target=_blank style='color:#2F92EE;'>#骨转移瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101887, encryptionId=6b9b10188e56, topicName=骨转移瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891f38632802, createdName=zhangj7121, createdTime=Tue Feb 14 00:21:08 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729548, encodeId=09c31e29548e1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jun 28 15:21:08 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076090, encodeId=461820e609057, content=<a href='/topic/show?id=8a3b93455ec' target=_blank style='color:#2F92EE;'>#转移瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93455, encryptionId=8a3b93455ec, topicName=转移瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Mon Jul 04 07:21:08 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218638, encodeId=0a20121863898, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Wed May 11 07:04:12 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218604, encodeId=52d1121860496, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=403c8157285, createdName=ms1000002127710105, createdTime=Tue May 10 23:07:15 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278270, encodeId=da9212e8270ce, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun May 08 04:21:08 CST 2022, time=2022-05-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1774632, encodeId=9ee91e7463248, content=<a href='/topic/show?id=6b9b10188e56' target=_blank style='color:#2F92EE;'>#骨转移瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101887, encryptionId=6b9b10188e56, topicName=骨转移瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891f38632802, createdName=zhangj7121, createdTime=Tue Feb 14 00:21:08 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729548, encodeId=09c31e29548e1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jun 28 15:21:08 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076090, encodeId=461820e609057, content=<a href='/topic/show?id=8a3b93455ec' target=_blank style='color:#2F92EE;'>#转移瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93455, encryptionId=8a3b93455ec, topicName=转移瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Mon Jul 04 07:21:08 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218638, encodeId=0a20121863898, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Wed May 11 07:04:12 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218604, encodeId=52d1121860496, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=403c8157285, createdName=ms1000002127710105, createdTime=Tue May 10 23:07:15 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278270, encodeId=da9212e8270ce, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun May 08 04:21:08 CST 2022, time=2022-05-08, status=1, ipAttribution=)]
    2022-06-28 仁医06
  3. [GetPortalCommentsPageByObjectIdResponse(id=1774632, encodeId=9ee91e7463248, content=<a href='/topic/show?id=6b9b10188e56' target=_blank style='color:#2F92EE;'>#骨转移瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101887, encryptionId=6b9b10188e56, topicName=骨转移瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891f38632802, createdName=zhangj7121, createdTime=Tue Feb 14 00:21:08 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729548, encodeId=09c31e29548e1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jun 28 15:21:08 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076090, encodeId=461820e609057, content=<a href='/topic/show?id=8a3b93455ec' target=_blank style='color:#2F92EE;'>#转移瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93455, encryptionId=8a3b93455ec, topicName=转移瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Mon Jul 04 07:21:08 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218638, encodeId=0a20121863898, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Wed May 11 07:04:12 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218604, encodeId=52d1121860496, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=403c8157285, createdName=ms1000002127710105, createdTime=Tue May 10 23:07:15 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278270, encodeId=da9212e8270ce, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun May 08 04:21:08 CST 2022, time=2022-05-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1774632, encodeId=9ee91e7463248, content=<a href='/topic/show?id=6b9b10188e56' target=_blank style='color:#2F92EE;'>#骨转移瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101887, encryptionId=6b9b10188e56, topicName=骨转移瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891f38632802, createdName=zhangj7121, createdTime=Tue Feb 14 00:21:08 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729548, encodeId=09c31e29548e1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jun 28 15:21:08 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076090, encodeId=461820e609057, content=<a href='/topic/show?id=8a3b93455ec' target=_blank style='color:#2F92EE;'>#转移瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93455, encryptionId=8a3b93455ec, topicName=转移瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Mon Jul 04 07:21:08 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218638, encodeId=0a20121863898, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Wed May 11 07:04:12 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218604, encodeId=52d1121860496, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=403c8157285, createdName=ms1000002127710105, createdTime=Tue May 10 23:07:15 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278270, encodeId=da9212e8270ce, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun May 08 04:21:08 CST 2022, time=2022-05-08, status=1, ipAttribution=)]
    2022-05-11 1064510_1039
  5. [GetPortalCommentsPageByObjectIdResponse(id=1774632, encodeId=9ee91e7463248, content=<a href='/topic/show?id=6b9b10188e56' target=_blank style='color:#2F92EE;'>#骨转移瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101887, encryptionId=6b9b10188e56, topicName=骨转移瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891f38632802, createdName=zhangj7121, createdTime=Tue Feb 14 00:21:08 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729548, encodeId=09c31e29548e1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jun 28 15:21:08 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076090, encodeId=461820e609057, content=<a href='/topic/show?id=8a3b93455ec' target=_blank style='color:#2F92EE;'>#转移瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93455, encryptionId=8a3b93455ec, topicName=转移瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Mon Jul 04 07:21:08 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218638, encodeId=0a20121863898, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Wed May 11 07:04:12 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218604, encodeId=52d1121860496, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=403c8157285, createdName=ms1000002127710105, createdTime=Tue May 10 23:07:15 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278270, encodeId=da9212e8270ce, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun May 08 04:21:08 CST 2022, time=2022-05-08, status=1, ipAttribution=)]
    2022-05-10 ms1000002127710105

    学到了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1774632, encodeId=9ee91e7463248, content=<a href='/topic/show?id=6b9b10188e56' target=_blank style='color:#2F92EE;'>#骨转移瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101887, encryptionId=6b9b10188e56, topicName=骨转移瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891f38632802, createdName=zhangj7121, createdTime=Tue Feb 14 00:21:08 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729548, encodeId=09c31e29548e1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jun 28 15:21:08 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076090, encodeId=461820e609057, content=<a href='/topic/show?id=8a3b93455ec' target=_blank style='color:#2F92EE;'>#转移瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93455, encryptionId=8a3b93455ec, topicName=转移瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Mon Jul 04 07:21:08 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218638, encodeId=0a20121863898, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Wed May 11 07:04:12 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218604, encodeId=52d1121860496, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=403c8157285, createdName=ms1000002127710105, createdTime=Tue May 10 23:07:15 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278270, encodeId=da9212e8270ce, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun May 08 04:21:08 CST 2022, time=2022-05-08, status=1, ipAttribution=)]
    2022-05-08 smlt2008

相关资讯

European Radiology:放射组学,让多发性骨髓瘤与转移瘤的鉴别不再头疼!

多发性骨髓瘤(MM)和转移瘤是两种最常见的椎体肿瘤,两者均可表现为软组织肿块或椎体破坏。由于发病年龄相似,其症状和影像学表现也有重叠,临床上可能出现误诊。然而,两种疾病的治疗方法却完全不同。

J Nucl Med:放射性药物177DOTA-ZOL治疗骨转移瘤的安全性和剂量评估

与其他放射性药物相比,177Lu-DOTA-ZOL治疗成骨细胞骨转移瘤是安全的,并且具有良好的治疗指数。

骨转移瘤的多种影像学诊断价值比较分析及病例介绍

       骨骼是恶性肿瘤第三常见的转移部位,仅次于肺和肝脏。恶性肿瘤主要通过血液循环转移到骨骼,通过静脉系统转移更为常见。早期发现骨转移对肿瘤患者治疗方案的制定和预后评价具有重要意义。影像学检查是为了早期发现骨转移,确定骨转移累及范围,评价有无骨相关事件(病

2018 EANM指南:骨转移瘤应用β放射性核素放射治疗

2018年2月,欧洲核医学协会(EANM)发布了骨转移瘤应用β放射性核素放射治疗指南,晚期癌症患者最常转移至骨,疼痛是肿瘤骨转移患者的主要健康问题。本文的主要目的是骨转移患者放射性核素治疗的评估,实施放射治疗,治疗结局以及副作用评估。

JNCCN:免疫检查点抑制剂治疗的转移性非小细胞肺癌(mNSCLC)患者骨转移、骨相关事件和生存关系

基线骨转移是免疫检查点抑制剂(ICIs)治疗转移性NSCLC较差的一个预后因素,而骨修复药物(BMAs)的应用并不能改善患者的预后。